Hereditary Hemorrhagic Telangiectasia in a Patient Undergoing Hemodialysis with Anticoagulants and Antiplatelets

Intern Med. 2024 Jun 1;63(11):1609-1614. doi: 10.2169/internalmedicine.2180-23. Epub 2023 Oct 20.

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder that causes abnormal blood vessel formation and bleeding. We herein report a 61-year-old woman with aggravated HHT symptoms after hemodialysis initiation. She was diagnosed with HHT based on her recurrent bleeding, abnormal blood vessel formation, and family history. Despite bleeding complications, the patient required anticoagulants and antiplatelet agents to treat cardiovascular complications. Eventually, the patient died of extensive cerebral hemorrhaging. Our experience suggests that special attention should be paid to bleeding complications in high-risk patients.

Keywords: Osler-Weber-Rendu disease; hemodialysis; hereditary hemorrhagic telangiectasia; pulmonary arteriovenous fistula.

Publication types

  • Case Reports

MeSH terms

  • Anticoagulants* / adverse effects
  • Anticoagulants* / therapeutic use
  • Fatal Outcome
  • Female
  • Humans
  • Middle Aged
  • Platelet Aggregation Inhibitors* / adverse effects
  • Platelet Aggregation Inhibitors* / therapeutic use
  • Renal Dialysis* / adverse effects
  • Telangiectasia, Hereditary Hemorrhagic* / complications

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors